GALT

Galectin TherapeuticsNasdaqCM:GALT Stock Report

Market Cap

US$222.3m

7D

0.5%

1Y

45.3%

Updated

22 Sep, 2021

Data

Company Financials +
GALT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

GALT Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Galectin Therapeutics
Historical stock prices
Current Share PriceUS$3.75
52 Week HighUS$1.82
52 Week LowUS$5.70
Beta2.35
1 Month Change3.88%
3 Month Change9.65%
1 Year Change45.35%
3 Year Change-39.22%
5 Year Change167.86%
Change since IPO-68.75%

Recent News & Updates

Jul 01

Galectin: Pursuing A Subset In The NASH Space

Galectin failed a phase 2 trial in 2017. However, the trial saw certain interesting features in a subset of patients. Galectin is pursuing this subset in another trial.

Shareholder Returns

GALTUS BiotechsUS Market
7D0.5%-0.9%-1.7%
1Y45.3%28.4%36.2%

Return vs Industry: GALT exceeded the US Biotechs industry which returned 26.1% over the past year.

Return vs Market: GALT exceeded the US Market which returned 31.5% over the past year.

Price Volatility

Is GALT's price volatile compared to industry and market?
GALT volatility
GALT Beta2.35
Industry Beta1.03
Market Beta1

Stable Share Price: GALT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: GALT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20006Joel Lewishttps://galectintherapeutics.com

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company’s lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis.

Galectin Therapeutics Fundamentals Summary

How do Galectin Therapeutics's earnings and revenue compare to its market cap?
GALT fundamental statistics
Market CapUS$222.28m
Earnings (TTM)-US$28.73m
Revenue (TTM)n/a

0x

P/S Ratio

-7.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GALT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$28.73m
Earnings-US$28.73m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.50
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio59.8%

How did GALT perform over the long term?

See historical performance and comparison

Valuation

Is Galectin Therapeutics undervalued compared to its fair value and its price relative to the market?

14.95x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GALT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GALT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GALT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GALT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GALT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GALT is overvalued based on its PB Ratio (15x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Galectin Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-16.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GALT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GALT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GALT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GALT is forecast to have no revenue next year.

High Growth Revenue: GALT is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GALT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Galectin Therapeutics performed over the past 5 years?

-2.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GALT is currently unprofitable.

Growing Profit Margin: GALT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GALT is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare GALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: GALT has a negative Return on Equity (-166.99%), as it is currently unprofitable.


Financial Health

How is Galectin Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: GALT's short term assets ($33.3M) exceed its short term liabilities ($6.1M).

Long Term Liabilities: GALT's short term assets ($33.3M) exceed its long term liabilities ($10.2M).


Debt to Equity History and Analysis

Debt Level: GALT's debt to equity ratio (59.8%) is considered high.

Reducing Debt: Insufficient data to determine if GALT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GALT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: GALT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 1.5% each year


Dividend

What is Galectin Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GALT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GALT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Joel Lewis (51 yo)

1

Tenure

US$1,233,720

Compensation

Mr. Joel Lewis serves as Chief Executive Officer and President at Galectin Therapeutics, Inc since September 2, 2020 and Director since December 14, 2017. He served as the Managing Director of Shareholder...


CEO Compensation Analysis

Compensation vs Market: Joel's total compensation ($USD1.23M) is about average for companies of similar size in the US market ($USD1.09M).

Compensation vs Earnings: Joel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: GALT's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: GALT's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.


Top Shareholders

Company Information

Galectin Therapeutics Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Galectin Therapeutics Inc.
  • Ticker: GALT
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$222.281m
  • Shares outstanding: 59.28m
  • Website: https://galectintherapeutics.com

Number of Employees


Location

  • Galectin Therapeutics Inc.
  • 4960 Peachtree Industrial Boulevard
  • Suite 240
  • Norcross
  • Georgia
  • 30071
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/22 22:37
End of Day Share Price2021/09/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.